Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR3 | P46089 | 2/20 | 0.42 |
| ▸ | KIF11 | P52732 | 2/20 | 0.41 |
| ▸ | CETP | P11597 | 2/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.39 |
| ▸ | PIM1 | P11309 | 1/20 | 0.39 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.39 |
| ▸ | DAO | P14920 | 1/20 | 0.39 |
| ▸ | MPI | P34949 | 1/20 | 0.39 |
| ▸ | XDH | P47989 | 1/20 | 0.39 |
| ▸ | GALR1 | P47211 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | SYK | P43405 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21363278 | 0.88 | XDH (0.44) | XDHGALR1 | |
| SCHEMBL3147185 | 0.84 | GPR3 (0.50) | GPR3KIF11CETPCHRM2CHRM1 | |
| SCHEMBL2095507 | 0.83 | KIF11 (0.32) | KIF11 | |
| Benzenethiol SCHEMBL29279994 | 0.80 | KIF11 (0.41) | GPR3KIF11EPHX2MAPTHTT | |
| SCHEMBL29993108 | 0.78 | KIF11 (0.41) | KIF11CETPALDH1A1HPGD | |
| SCHEMBL28088141 | 0.78 | GPR3 (0.42) | GPR3KIF11CETPCHRM2CHRM1 | |
| SCHEMBL2092201 | 0.78 | KIF11 (0.41) | KIF11CETPALDH1A1HPGD | |
| SCHEMBL2094855 | 0.77 | GPR3 (0.45) | GPR3KIF11CETPCHRM2CHRM1 | |
| SCHEMBL2091562 | 0.77 | GPR3 (0.39) | GPR3KIF11PIM1EPHX2GAA | |
| SCHEMBL24315321 | 0.76 | ADORA1 (0.41) | XDHGALR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 174 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3547414-B1 | LITHIUM ELECTRODE AND LITHIUM SECONDARY BATTERY COMPRISING SAME | LG ENERGY SOLUTION LTD (KR) | 2023-09-13 | — | — | EP | claimed |
| EP-3664213-B1 | ELECTROLYTE FOR LITHIUM METAL BATTERY AND LITHIUM METAL BATTERY COMPRISING SAME | LG ENERGY SOLUTION LTD (KR) | 2023-09-13 | — | — | EP | claimed |
| US-11495824-B2 | Electrolyte for lithium metal battery and lithium metal battery comprising same | LG ENERGY SOLUTION, LTD. (KR) | 2022-11-08 | — | — | US | claimed |
| CN-110192294-B | Lithium electrode and lithium secondary battery comprising same | 株式会社LG新能源 | 2022-09-20 | — | — | CN | claimed |
| CN-111033864-B | Electrolyte for lithium metal battery and lithium metal battery comprising same | 株式会社LG新能源 | 2022-08-12 | — | — | CN | claimed |
| US-20200203759-A1 | ELECTROLYTE FOR LITHIUM METAL BATTERY AND LITHIUM METAL BATTERY COMPRISING SAME | LG CHEM, LTD. (KR) | 2020-06-25 | — | — | US | claimed |
| EP-3664213-A2 | ELECTROLYTE FOR LITHIUM METAL BATTERY AND LITHIUM METAL BATTERY COMPRISING SAME | LG Chem, Ltd. (KR) | 2020-06-10 | — | — | EP | claimed |
| US-20190319272-A1 | LITHIUM ELECTRODE AND LITHIUM SECONDARY BATTERY COMPRISING SAME | LG CHEM, LTD. (KR) | 2019-10-17 | — | — | US | claimed |
| EP-3547414-A2 | LITHIUM ELECTRODE AND LITHIUM SECONDARY BATTERY COMPRISING SAME | LG Chem, Ltd. (KR) | 2019-10-02 | — | — | EP | claimed |
| US-20250314585-A1 | LOCALISED SURFACE PLASMONIC SENSING | THE UNIVERSITY COURT OF THE UNIVERSITY OF GLASGOW (GB) | 2025-10-09 | — | — | US | disclosed |
| US-12336981-B2 | Compounds and compositions for the inhibition of NAMPT | VALO HEALTH, INC. (US) | 2025-06-24 | — | — | US | disclosed |
| CN-114671864-B | Heteroaryl substituted pyridines and methods of use | 艾伯维公司 | 2025-04-08 | — | — | CN | disclosed |
| US-20250099448-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2025-03-27 | — | — | US | disclosed |
| EP-4526660-A1 | LOCALISED SURFACE PLASMONIC SENSING | The University Court Of The University Of Glasgow (GB) | 2025-03-26 | — | — | EP | disclosed |
| WO-2007073497-A2 | CALCIUM CHANNEL ANTAGONISTS | ICAGEN, INC. (US) | 2007-06-28 | — | — | WO | disclosed |
| WO-2006073366-A1 | NON-ANILINIC DERIVATIVES OF ISOTHIAZOL-3(2H)-ONE 1,1-DIOXIDES AS LIVER X RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2006-07-13 | — | — | WO | disclosed |
| US-20060111347-A1 | Substituted sulfones and methods of use | AMGEN INC. (US) | 2006-05-25 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| WO-2006041888-A2 | SUBSTITUTED ARYL OR HETEROARYLSULFONYLBUTANAMIDES FOR USE AS ANTI-INFLAMMATORY AGENTS | AMGEN INC. (US) | 2006-04-20 | — | — | WO | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | GPR3 80/4885KIF11 3946/4885CETP 4769/4885 |
| US-12336981-B2 | Compounds and compositions for the inhibition of NAMPT | NAMPT, NNMT, NNT | GPR3 2645/4885KIF11 4133/4885CETP 674/4885 |
| US-20250099448-A1 | HETEROCYCLIC COMPOUNDS | OPRM1, CYP1A1, CYP3A4 | GPR3 1582/4885KIF11 3738/4885CETP 4155/4885 |
| US-20060111347-A1 | Substituted sulfones and methods of use | SULT2A1, STS, SULT1A1 | GPR3 1337/4885KIF11 4847/4885CETP 2211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.